Respiro Diagnostics, a UK-based startup developing breath-based diagnostics for lungdiseases, has raised £1 million in a pre-seed funding round led by Zinc Venture Capital and SFC Capital. The round a...
The increased focus on proactive and non-invasive diagnostics, particularly post-pandemic, is driving innovation and investment in healthtech solutions like breath-based diagnostics.
This development indicates continued growth in digital health and early disease detection, impacting healthcare delivery models and potentially improving patient outcomes significantly.
The availability of more convenient and less invasive diagnostic tools for lung diseases could lead to earlier detection and more effective intervention strategies, shifting clinical practice slightly.
- · Respiro Diagnostics
- · Healthtech investors
- · Patients with lung diseases
- · Diagnostic device manufacturers
- · Traditional diagnostic methods
- · Companies slow to innovate in non-invasive diagnostics
Respiro Diagnostics secures funding to further develop its breath-based lung diagnostics technology.
Successful deployment of this technology could reduce healthcare costs associated with late-stage disease management and invasive procedures.
Widespread adoption might pave the way for similar non-invasive diagnostic approaches for other diseases, creating new market segments in preventative health.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at Tech.eu